$3.97
0.010.25%
Last update: Nov 11, 10:11 AM
GT Biopharma Inc
GTBPNASDAQ
The average analyst price target for GT Biopharma is $275, 6827.0% above the current price. The one analyst covering it rates it Buy. The latest change came on Dec 2, 2024, when Roth MKM initiated coverage of GT Biopharma with a Buy rating and a $275 price target.
Price Target Range — 1 Quarters
Analyst Consensus — 1 Analysts
Rating Trend — Last 9 Months
